What question did this study set out to answer?

This review evaluates the effectiveness and safety of drug treatments for cerebellar ataxia in children with ataxia-telangiectasia.

July 4, 2026Open Access

View Full Paper

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia‐Telangiectasia: A Systematic Review

FPFabiola PanvinoSapienza University of Rome RPRoberto PaparellaPoliclinico Umberto I GUGiorgia UrciuoloSapienza University of Rome

Key Points

This review evaluates the effectiveness and safety of drug treatments for cerebellar ataxia in children with ataxia-telangiectasia.
Conducted systematic searches across MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov until December 2025.
Included randomized controlled trials and single-arm interventional studies on pharmacological treatments for pediatric ataxia-telangiectasia.
Analyzed thirteen studies involving 314 participants with interventions such as betamethasone and nicotinamide riboside.
Betamethasone showed transient improvements in SARA and ICARS scores, but with systemic toxicity.
eDSP was ineffective in phase 3 trials, though it suggested potential benefits for children aged 6-9 in subgroup analyses.
NR supplementation improved SARA and AT-NEST scores in open-label studies.

Abstract

INTRODUCTION: Ataxia-telangiectasia (AT) is characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, and increased cancer susceptibility. No disease-modifying treatment is available. This systematic review aimed to evaluate the efficacy and safety of pharmacological interventions for ataxia in pediatric AT. METHOD: A systematic search was conducted across MEDLINE, Scopus, Web of Science, and ClinicalTrials.gov through December 2025. Eligible studies included randomized controlled trials (RCTs) and single-arm interventional studies evaluating pharmacological treatments for cerebellar ataxia in patients aged ≤ 18 years with genetically confirmed AT. RESULTS: Thirteen studies (3 RCTs, 10 single-arm trials) involving 314 participants (mean age 10.87 years) were included. Interventions included betamethasone, erythrocyte-encapsulated dexamethasone (eDSP), nicotinamide riboside (NR), leucine derivatives, and amantadine. Betamethasone demonstrated transient improvements in the Scale for the Assessment and Rating of Ataxia (SARA) and International Cooperative Ataxia Rating Scale (ICARS) scores, with dose-dependent systemic toxicity. eDSP showed favorable tolerability but was ineffective in phase 3 trials, although subgroup analyses suggested a potential benefit in children aged 6-9 years. NR supplementation improved SARA and AT Neurological Examination Scale Toolkit (AT-NEST) scores in open-label studies. Leucine derivatives showed mixed results. Amantadine showed benefits in patients with extrapyramidal symptoms. CONCLUSIONS: The recurrent pattern of promising open-label findings followed by negative phase 3 results highlights a translational gap attributable to methodological limitations, including small sample sizes, heterogeneous populations, and variable outcome measures. The non-linear disease progression and age-dependent treatment response further complicate trial design. Current evidence remains insufficient to guide clinical practice. TRIAL REGISTRATION: PROSPERO number: CRD420251184721.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia‐Telangiectasia: A Systematic Review

Key Points

Abstract

Cite This Study

Also Consider

Also Consider